Tty Biopharm Company Limited · TPEX:4105
Tty Biopharm — Q3 2024 Earnings Presentation
12 slides from Tty Biopharm's earnings presentation, Nov 27, 2024
Slide 1: TTY Biopharm Operational Results Report
TTY Biopharm 4105 Operational Results Report 2024.11.27
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, TTY Biopharm cautions that this foregoing list of factors is not ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’,
Slide 3: Q1~Q3/2024 Operational Highlights
Operational Results Report Q1~Q3/2024 Operational Highlights Q1~Q3/2024 Financial Performance 01 Q1~Q3/2024 Operational Highlights 2024 Outlook 2
Slide 4: Strong Revenue with Overseas Market Expansion
Strong Revenue with Overseas Market Expansion Operational Results Report Revenue Overview √ YoY Consolidated Revenue √ Consolidated Operating √ EPS remained app. the same Q1~Q3/2024 Operational +8% (4.18 billion) Gross Margin 61% as same period last year $3.7 Highlights Market Development Highlights
Slide 5: Three Arrows of Operation with Outstanding Results
Three Arrows of Operation with Outstanding Results Operational Results Report Export the Difficulty Generic Drugs • Received milestone from overseas market of long-lasting microsphere drug, OT2015. Q1~Q3/2024 • Received milestone from European market of liposome products, Amphotericin B, Lipo-AB. Op
Slide 6: Product Pipeline: Self-develop, License-in, Cooperation
Product Pipeline: Self-develop, License-in, Cooperation Operational Results Report • Alliance with international partners to strengthen the advantage of the product portfolio • Joint-develop specialty of generic drugs with international partners and expand overseas markets Q1~Q3/2024 Oncology 2024 2
Slide 7: Deploy Globally and Expand Overseas Market
Deploy Globally and Expand Overseas Market Operational Results Report • License-in/ collaboration/ sales 130 drugs in 18 countries globally. • The export market will continue to grow and expand steadily, focusing on the development of the US and other major markets. Q1~Q3/2024 • Deepen cooperation w
Slide 8: Q1~Q3/2024 Financial Performance
Operational Results Report Q1~Q3/2024 Operational Highlights Q1~Q3/2024 Financial Performance 02 Q1~Q3/2024 Financial Performance 2024 Outlook 7
Slide 9: Q1~Q3/2024 Financial Performance
Q1~Q3/2024 Financial Performance Operational Results Report Income Statement （Unit: NT Thousand, Q1~Q3/2024 Q1~Q3/2023 YoY % Q1~Q3 ‘24 Financial Performance Q1~Q3/2024 except EPS） Operational • YoY consolidated revenue was 4.18 billion, +8% due to the Net Sales 4,181,720 3,860,775 +8% Highlights hig
Slide 10: Steady Revenue Growth: Revenue Breakdown
1H/2024 Steady Revenue Growth Operational Results Report Q1~Q3/2024 Revenue Breakdown Q1~Q3/2024 Revenue Growth Q1~Q3/2024 Operational Highlights Product Category % Revenue (NT Mn) 4,300 19% 41 Oncology 41% 103 -8 3% 4,200 4,182 Q1~Q3/2024 -26 Financial Intensive Care -27 Performance 238 Healthcare
Slide 11: 2024 Outlook
Operational Results Report Q1~Q3/2024 Operational Highlights Q1~Q3/2024 Financial Performance 03 2024 Outlook 2024 Outlook 10
Slide 12: Core Strategy and the Three Arrows are Implemented
Core Strategy and the Three Arrows are Implemented Operational Results Report 1 Strengthen Global Deployment Q1~Q3/2024 Explore potential products and expand international market through Operational authorization, distribution, strategic cooperation and M&A. Highlights License-in the International N